Warfarin vs. Asprin in Reduced Ejection Fraction

03.08.2013 • Views

Share Embed Flag

Warfarin vs. Asprin in Reduced Ejection Fraction

Warfarin vs. Asprin in Reduced Ejection Fraction

DOWNLOAD ePAPER

conference.cast.com

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

Thank you to:<br />

• Site <strong>in</strong>vestigators and<br />

coord<strong>in</strong>ators<br />

• CCC and SAC team members<br />

• CEC Committee members<br />

• DSMB members<br />

• NINDS<br />

• All study volunteers

Previous page
Next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

S. aureus

Centers for Disease Control and Prevention

ABMM/ABMLI Professional Recognition Award

The Riata® Implantable Cardioverter Defibrillator Lead: Extraction ...

ECEF PULSE 2011

Enlarged Perivascular Spaces in Lacunar Stroke

Hemostatic therapy for treatment of oral anticoagulation-related ICH

EXHIBITOR INVITES

Molecular vs non-Molecular Testing for MRSA/MSSA: The Case for ...

B. fragilis

Virtual Meeting RFP: Heart Rhythm Society

Regulation of Laboratory Developed Tests

The Tell-Tale Stain

Clinically Relevant, Cost-Effective Microbiology

Thank you to: • Site <strong>in</strong>vestigators and coord<strong>in</strong>ators • CCC and SAC team members • CEC Committee members • DSMB members • NINDS • All study volunteers

Page 1 and 2: WARFARIN vs. ASPIRIN in REDUCED CAR
Page 3 and 4: Background • Heart failure patien
Page 5 and 6: Key Inclusion Criteria 1. Normal si
Page 7 and 8: Statistical Design • Primary null
Page 9 and 10: Randomized, n Lost to Follow-up, n
Page 11 and 12: Baseline Medication Time in Therape
Page 13 and 14: Warfarin vs. Aspirin Hazard Ratios
Page 15 and 16: No. at risk Main Secondary Outcome
Page 17 and 18: Conclusions • No overall differen
Page 19: STUDY ORGANIZATION Sponsor - the Na